Mycobacterium specific ATP synthase inhibitors as Anti-tubercular drug

Mycobacterium tuberculosis is a causative agent of tuberculosis. More than one third of the world population are infected with TB bacilli. After AIDS, tuberculosis is the leading cause of death among infectious diseases in the world. Bedaquiline, the lead compound of the DARQ series,. It also shows a selectivity of > 20,000:1 towards mycobacterial ATP synthase as compared to human mitochondrial ATP synthase. Bedaquiline was recently approved for use by the U.S. Food and Drug Administration (FDA) against Multi-drug resistant TB (MDR-TB). Some new pharmacophores have been reported that are showing Anti-TB activity. For example quinoline based compounds containing aryl allyl ether were reported to have promising activity. Quinoline are well-known pharmacophore in medicinal chemistry showing promising activity against various diseases such as antimalaria, antimicrobial and antituberculosis activity.